Anti-inflammatory effects of Rhizopus spp. fermentation products on ovalbumin-induced asthma in mice

Abstract

Fermentation by Rhizopus spp. has been used as a traditional medicine for treating various inflammatory diseases. Allergic asthma is a chronic respiratory disease that is caused by an exaggerated immune response. This study was conducted to ascertain the anti-inflammatory effects of Rhizopus spp. fermentation extract (RU) on a mouse model of ovalbumin (OVA)-induced asthma. The animals were intraperitoneally injected OVA on day 1 and 7, followed by OVA intranasal inhalation on days 14 to 18. The animals were treated daily with RU (100 and 200 mg/kg) by oral gavage from day 18 to day 23. RU significantly decreased eosinophilia and the production of inflammatory cytokines and OVA specific immunoglobulin E in animals with asthma, along with reducing airway inflammation and mucus secretion in lung tissue. Histological changes in the lungs and levels of inflammatory mediators of allergic airway inflammation were evaluated. The regulatory effects of RU on type 2 helper T (Th2) cell activation were investigated. RU administration attenuated asthmatic changes such as inflammatory cell infiltration and mucus production, decreased the levels of Th2-related cytokines, and reduced Th2 cell activation. Administration of RU effectively reduced allergic responses in asthmatic mice, which is associated with regulating Th2 cell activation and differentiation. These results indicate that RU can attenuate the respiratory symptoms of asthma.